Psychopharmacology

, Volume 184, Issue 3–4, pp 628–636 | Cite as

Medication screening for smoking cessation: a proposal for new methodologies

  • Kenneth A. Perkins
  • Maxine Stitzer
  • Caryn Lerman
Review

Abstract

Rationale

The purpose of medication screening studies is to quickly and cheaply evaluate the clinical potential of medications, so that promising drugs proceed to large-scale clinical trials and unpromising drugs do not. Screening procedures for smoking cessation medications either are not sufficiently practical or lack clinical validity. Clinical trials have clinical validity but are often impractical as initial tests of efficacy (i.e., screening) or suffer from limited statistical power. The alternative approach of short-term, laboratory-based studies of purported mechanisms of efficacy may overcome some of the practical problems of clinical trials but appear to have limited clinical validity.

Objectives

This commentary identifies some of the limitations of current short-term screening procedures and provides suggestions for improving such studies.

Results

Short-term screening studies typically use smokers unmotivated to abstain (i.e., nontreatment seekers) as participants and examine brief medication effects on clinical markers or potential mechanisms of action, including relief of withdrawal and craving during enforced abstinence or on reduction in the reinforcing effects of smoked tobacco. The limitation of these approaches is shown by their insensitivity to effects of nicotine replacement and bupropion, which are effective in clinical trials for smoking cessation.

Conclusions

The clinical validity of short-term screening studies may improve if these studies simulate some clinical trial procedures within practical limitations. Thus, they should recruit smokers motivated to abstain, emphasize smoking abstinence as a primary index of medication response, examine effects over sufficiently long time periods to encompass the drug's mechanism of action, and assess responses in the natural environment. Whether these changes improve the sensitivity of screening studies is testable. Other research aimed specifically at identifying the mechanisms of therapeutic action of a medication may also profit from using this approach of simulating a short-term clinical trial.

Keywords

Smoking cessation Pharmacotherapy Medication screening Nicotine dependence 

Notes

Acknowledgements

Preparation of this manuscript was supported by grants DA16483 (K.A.P.), P50 DA/CA84718 and DA017555 (C.L.), and CA99241 (M.S.). The authors thank Mitch Nides and Saul Shiffman for their helpful comments during discussions of this topic.

References

  1. Alessi SM, Badger GJ, Higgins ST (2004) An experimental examination of the initial weeks of abstinence in smokers. Exp Clin Psychopharmacol 12:276–287CrossRefPubMedGoogle Scholar
  2. Benowitz NL, Peng MW (2000) Non-nicotine pharmacotherapy for smoking cessation. CNS Drugs 13:265–285CrossRefGoogle Scholar
  3. Benowitz NL, Zevin S, Jacob P (1998) Suppression of nicotine intake during ad libitum cigarette smoking by high-dose transdermal nicotine. J Pharmacol Exp Ther 287:958–962PubMedGoogle Scholar
  4. Caggiula AR, Donny EC, White AR, Chaudhri N, Booth S, Gharib MA, Hoffman A, Perkins KA, Sved AF (2001) Cue dependence of nicotine self-administration and smoking. Pharmacol Biochem Behav 70:515–530CrossRefPubMedGoogle Scholar
  5. Carter BL, Tiffany ST (1999) Meta-analysis of cue-reactivity in addiction research. Addiction 94:327–340CrossRefPubMedGoogle Scholar
  6. Chornock WM, Stitzer ML, Gross J, Leischow S (1992) Experimental model of smoking re-exposure: effects on relapse. Psychopharmacology (Berl) 108:495–500CrossRefGoogle Scholar
  7. Conklin CA, Tiffany ST (2002) Applying extinction research and theory to cue-exposure addiction treatments. Addiction 97:155–167CrossRefPubMedGoogle Scholar
  8. Cousins MS, Stamat HM, de Wit H (2001) Acute doses of d-amphetamine and bupropion increase cigarette smoking. Psychopharmacology (Berl) 157:243–253CrossRefGoogle Scholar
  9. Etter JF, Sutton S (2002) Assessing ‘stage of change’ in current and former smokers. Addiction 97:1171–1182CrossRefPubMedGoogle Scholar
  10. Etter JF, Laszlo E, Zellweger JP, Perrot C, Perneger TV (2002) Nicotine replacement to reduce cigarette consumption in smokers who are unwilling to quit: a randomized trial. J Clin Psychopharmacol 22:487–495CrossRefPubMedGoogle Scholar
  11. Ezzati M, Lopez AD (2004) Regional, disease specific patterns of smoking-attributable mortality in 2000. Tob Control 13:388–395CrossRefPubMedGoogle Scholar
  12. Gilbert DF, Crauthers DM, Mooney DK, McClernon FJ, Jensen RA (1999) Effects of monetary contingencies on smoking relapse: influences of trait depression, personality, and habitual nicotine intake. Exp Clin Psychopharmacol 7:174–181CrossRefPubMedGoogle Scholar
  13. Hatsukami DK, Dahlgren L, Zimmerman R, Hughes JR (1988) Symptoms of tobacco withdrawal from total cigarette cessation versus partial cigarette reduction. Psychopharmacology (Berl) 94:242–247CrossRefGoogle Scholar
  14. Hatsukami DK, Jensen J, Allen S, Grillo M, Bliss R (1996) Effects of behavioral and pharmacological treatment on smokeless tobacco users. J Consult Clin Psychol 64:153–161CrossRefPubMedGoogle Scholar
  15. Hatsukami DK, Pentel PR, Jensen J, Nelson D, Allen SS, Goldman A, Rafael D (1998) Cotinine: effects with and without nicotine. Psychopharmacology (Berl) 135:141–150CrossRefGoogle Scholar
  16. Hatsukami DK, Henningfield JE, Kotlyar M (2004) Harm reduction approaches to reducing tobacco-related mortality. Annu Rev Public Health 25:377–395CrossRefPubMedGoogle Scholar
  17. Havermans RC, Debaere S, Smulders FTY, Wiers RW, Jansen ATM (2003) Effect of cue exposure, urge to smoke, and nicotine deprivation on cognitive performance in smokers. Psychol Addict Behav 17:336–339CrossRefPubMedGoogle Scholar
  18. Hughes JR, Hatsukami DK, Pickens RW, Krahn D, Malin S, Luknic A (1984) Effect of nicotine on the tobacco withdrawal syndrome. Psychopharmacology (Berl) 83:82–87CrossRefGoogle Scholar
  19. Hughes JR, Stead L, Lancaster T (1999) Anxiolytics and antidepressants for smoking cessation. Cochrane Database Syst Rev 4:CD000031Google Scholar
  20. Hughes JR, Stead L, Lancaster T (2004) Antidepressants for smoking cessation. Cochrane Database Syst Rev 4:CD000031PubMedGoogle Scholar
  21. Hurt RD, Sachs DPL, Glover ED, Offord KP, Johnston JA, Dale LC, Khayrallah MA, Schroeder DR, Glover PN, Sullivan CR, Croghan IT, Sullivan PM (1997) A comparison of sustained-release bupropion and placebo for smoking cessation. N Engl J Med 337:1195–1202CrossRefPubMedGoogle Scholar
  22. Hurt RD, Offord KP, Croghan IT, Croghan GA, Gomez-Dahl LC, Wolter TD, Dale LC, Moyer TP (1998) Temporal effects of nicotine nasal spray and gum on nicotine withdrawal symptoms. Psychopharmacology (Berl) 140:98–104CrossRefGoogle Scholar
  23. Irvin JE, Brandon TH (2000) The increasing recalcitrance of smokers in clinical trials. Nicotine Tob Res 2:79–84CrossRefPubMedGoogle Scholar
  24. Johnson MW, Bickel WK, Kirshenbaum AP (2004) Substitutes for tobacco smoking: a behavioral economic analysis of nicotine gum, denicotinized cigarettes, and nicotine-containing cigarettes. Drug Alcohol Depend 74:253–264CrossRefPubMedGoogle Scholar
  25. Jorenby DE, Keehn DS, Fiore MC (1995) Comparative efficacy and tolerability of nicotine replacement therapies. CNS Drugs 3:227–236CrossRefGoogle Scholar
  26. Kaufmann V, Jepson C, Rukstalis M, Perkins K, Audrain-McGovern J, Lerman C (2004) Subjective effects of an initial dose of nicotine nasal spray predict treatment outcome. Psychopharmacology (Berl) 172:271–276CrossRefGoogle Scholar
  27. Kenford SL, Smith SS, Wetter DW, Jorenby DE, Fiore MC, Baker TB (2002) Predicting relapse back to smoking: contrasting affective and physical models of dependence. J Consult Clin Psychol 70:216–227CrossRefPubMedGoogle Scholar
  28. Killen JD, Fortmann SP (1997) Craving is associated with smoking relapse: findings from three prospective studies. Exp Clin Psychopharmacol 5:137–142CrossRefPubMedGoogle Scholar
  29. Kraemer HC (1991) To increase power in randomized clinical trials without increasing sample size. Psychopharmacol Bull 27:217–224PubMedGoogle Scholar
  30. Kroboth PD, Schmith VD, Smith RB (1991) Pharmacodynamic modeling: application to new drug development. Clin Pharmacokinet 20:91–98PubMedCrossRefGoogle Scholar
  31. Lerman C, Niaura R, Collins BN, Wileyto P, Hawk L, Epstein LH, Audrain-McGovern J, Pinto A (2004) Effect of bupropion on depression symptoms in a smoking cessation clinical trial. Psychol Addict Behav 18:362–366CrossRefPubMedGoogle Scholar
  32. LeSage MG, Keyler DE, Collins G, Pentel PR (2003) Effects of continuous nicotine infusion on nicotine self-administration in rats: relationship between continuously infused and self-administered nicotine doses and serum concentrations. Psychopharmacology (Berl) 170:278–286CrossRefGoogle Scholar
  33. Martinez-Raga J, Keaney F, Sutherland G, Perez-Galvez B, Strang J (2003) Treatment of nicotine dependence with bupropion SR: review of its efficacy, safety and pharmacological profile. Addict Biol 8:13–21CrossRefPubMedGoogle Scholar
  34. Nemeth-Coslett R, Henningfield JE (1986) Effects of nicotine chewing gum on cigarette smoking and subjective and physiologic effects. Clin Pharmacol Ther 39:625–630PubMedCrossRefGoogle Scholar
  35. Nemeth-Coslett R, Henningfield JE, O'Keeffe MK, Griffiths RR (1987) Nicotine gum: dose-related effects on cigarette smoking and subjective ratings. Psychopharmacology (Berl) 92:424–430CrossRefGoogle Scholar
  36. Niaura R, Abrams D, DeMuth B, Pinto R, Monti P (1989) Responses to smoking-related stimuli and early relapse to smoking. Addict Behav 14:419–428CrossRefPubMedGoogle Scholar
  37. O'Brien CP (1997) A range of research-based pharmacotherapies for addiction. Science 278:66–70CrossRefPubMedGoogle Scholar
  38. Perkins KA, Grobe JE, Weiss D, Fonte C, Caggiula A (1996) Nicotine preference in smokers as a function of smoking abstinence. Pharmacol Biochem Behav 55:257–263CrossRefPubMedGoogle Scholar
  39. Perkins KA, Broge M, Gerlach D, Sanders M, Grobe JE, Cherry C, Wilson AS (2002) Acute nicotine reinforcement, but not chronic tolerance, predicts withdrawal and relapse after quitting smoking. Health Psychol 21:332–339CrossRefPubMedGoogle Scholar
  40. Perkins KA, Lerman C, Keenan J, Fonte C, Coddington S (2004) Rate of nicotine onset from NRT and acute responses in smokers. Nicotine Tob Res 6:501–507CrossRefPubMedGoogle Scholar
  41. Pickworth WB, Bunker EB, Henningfield JE (1994) Transdermal nicotine: reduction of smoking with minimal abuse liability. Psychopharmacology (Berl) 115:9–14CrossRefGoogle Scholar
  42. Rukstalis M, Jepson C, Strasser A, Lynch KG, Perkins KA, Patterson F, Lerman CA (2005) Naltrexone reduces the relative reinforcing value of nicotine in a cigarette smoking choice paradigm. Psychopharmacology (Berl) 181:41–48CrossRefGoogle Scholar
  43. Shiffman S, Johnston JA, Khayrallah M, Elash CA, Gwaltney CJ, Paty JA, Evoniuk G, DeVeaugh-Geiss J (2000) The effect of bupropion on nicotine craving and withdrawal. Psychopharmacology (Berl) 148:33–40CrossRefGoogle Scholar
  44. Shoaib M, Sidhpura N, Shafait S (2003) Investigating the actions of bupropion on dependence-related effects of nicotine in rats. Psychopharmacology (Berl) 165:405–412Google Scholar
  45. Silagy C, Lancaster T, Stead L, Mant D, Fowler G (2004) Nicotine replacement therapy for smoking cessation. Cochrane Database Syst Rev 3:CD000146PubMedGoogle Scholar
  46. Stitzer ML, Rand CS, Below GE, Mead AM (1986) Contingent payment procedures for smoking reduction and cessation. J Appl Behav Anal 19:197–202PubMedCrossRefGoogle Scholar
  47. Stone AA, Shiffman S (2002) Capturing momentary, self-report data: a proposal for reporting guidelines. Ann Behav Med 24:236–243CrossRefPubMedGoogle Scholar
  48. Tang JL, Law M, Wald N (1994) How effective is nicotine replacement therapy in helping people to stop smoking? BMJ 308:21–26PubMedGoogle Scholar
  49. Teneggi V, Tiffany ST, Squassante L, Milleri S, Ziviani L, Bye A (2002) Smokers deprived of cigarettes for 72 h: effect of nicotine patches on craving and withdrawal. Psychopharmacology (Berl) 164:177–187CrossRefGoogle Scholar
  50. Tiffany ST, Cox LS, Elash CA (2000) Effects of transdermal nicotine patches on abstinence-induced and cue-elicited craving in cigarette smokers. J Consult Clin Psychol 68:233–240CrossRefPubMedGoogle Scholar
  51. Transdermal Nicotine Study Group (1991) Transdermal nicotine for smoking cessation. JAMA 266:3133–3138CrossRefGoogle Scholar
  52. Vocci FJ (1996) Development of medications for addictive disorders. In: Schuster CR, Kuhar M (eds) Handbook of experimental pharmacology, vol 118: pharmacological aspects of drug dependence, towards an integrated neurobehavioral approach. Springer, Berlin Heidelberg New York, pp 473–485Google Scholar
  53. Waters AJ, Shiffman S, Sayette MA, Paty JA, Gwaltney CJ, Balabanis MH (2004) Cue-provoked craving and nicotine replacement therapy in smoking cessation. J Consult Clin Psychol 72:1136–1143CrossRefPubMedGoogle Scholar
  54. West R, Shiffman S (2001) Effect of oral nicotine dosing forms on cigarette withdrawal symptoms and craving: a systematic review. Psychopharmacology (Berl) 155:115–122CrossRefGoogle Scholar
  55. Zernig G, de Wit H, Telser S, Nienhusmeier M, Wakonigg G, Sturm K, Berger I, Kemmler G, Saria A (2004) Subjective effects of slow-release bupropion versus caffeine as determined in a quasi-naturalistic setting. Pharmacology 70:206–215CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag 2005

Authors and Affiliations

  • Kenneth A. Perkins
    • 1
  • Maxine Stitzer
    • 2
  • Caryn Lerman
    • 3
  1. 1.WPICUniversity of Pittsburgh School of MedicinePittsburghUSA
  2. 2.BPRUBaltimoreUSA
  3. 3.Transdisciplinary Tobacco Use Research Center, Department of Psychiatry and Annenberg Public Policy CenterAbramson Cancer Center of the University of PennsylvaniaPhiladelphiaUSA

Personalised recommendations